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Recent Advances in Iridium(I) Catalysis towards 
Directed Hydrogen Isotope Exchange 
 
William J. Kerr,a* Gary J. Knox,a and Laura C. Patersona 
 
The initial discovery and establishment of a family of novel iridium catalysts 
possessing N-heterocyclic carbene units alongside bulky phosphine ligands allowed 
selected substrates to be labelled using deuterium or tritium gas at desirably low 
catalyst loadings via an ortho-directed C-H insertion process.  Such a method has 
broad applicability and offers distinct advantages within the pharmaceutical industry, 
directly facilitating the ability to carefully monitor a potential drug molecule’s biological 
fate.  Over the past decade since these initial protocols were divulged, many additional 
advances have been made in terms of catalyst design and substrate scope.  This review 
describes the broadened array of new iridium catalysts and associated protocols for 
direct and selective C-H activation and hydrogen isotope insertion within a number of 
new chemical entities of direct relevance to the pharmaceutical industry.  
Keywords: hydrogen isotope exchange; N-heterocyclic carbene; deuteration; tritiation; 
iridium. 
 
INTRODUCTION 
Despite vast financial commitment to drug discovery, the global pharmaceutical industry faces 
significant attrition rates of drug candidate molecules in preclinical trials.  Relating to this, early 
metabolism studies are central to addressing these prominent issues.  A method of 
considerable importance in this arena is labelling by hydrogen isotope exchange (HIE),1 which 
directly facilitates the careful monitoring of a potential drug molecule’s biological fate.  The 
exchange of hydrogen in a C-H bond by deuterium or tritium through directing group assisted 
ortho-HIE represents a direct and economical method of generating isotopically-labelled 
molecules (Scheme 1).1,2 
 
 
Scheme 1: ortho-Directed Hydrogen Isotope Exchange. 
 
Due to the growing demand for deuterium- and tritium-labelled compounds for use in 
determining the pharmacokinetics of active pharmaceutical ingredients (APIs), and in 
mechanistic studies within the wider chemistry community, there has been increased focus on 
the development of catalysts capable of facilitating HIE in a mild, efficient, and selective 
manner.3  The literature in this area is well established with labelling techniques utilising a 
range of complexes of Pt,4 Rh,5 Ru,6 and Ir7 already disclosed. Having stated this, it is the 
complexes of iridium that have garnered considerable more recent attention.  As related to 
this, processes with Ir have been historically performed using Crabtree’s catalyst 3,8 as first 
disclosed by Hesk and Heys.9  However, the necessity for a high, and often stoichiometric, 
catalyst loading when considering a wider range of substrates10 led to attention being turned 
to alternative and more specifically tuned catalyst species in recent years.  In this regard, in 
2008 our laboratory disclosed the use of novel iridium(I) carbene complexes of type 4 (Figure 
1),11 which offered immediate advantages over Crabtree’s catalyst in terms of catalyst 
efficiency and applicability, as well as a notable reduction in radioactive waste production 
resulting from tritiation experiments.11b  Compounds 4a-c (now commercialised by Strem 
Chemicals) are robust and readily handled materials, and, owning to the steric bulk and 
electronic balance of the NHC/phosphine combination, these complexes emerged as some of 
the most active species in the HIE domain at the time.  An array of functional groups such as 
ketones, amides, and heterocyclic substrates were recognised as applicable with catalysts 4a-
c in ortho-directed hydrogen isotope exchange processes.11 
 
  
 
 
Figure 1: Iridium(I) Catalysts for HIE. 
 
Following on from this work from our laboratory, this field of iridium catalysis has been further 
diversified over the last decade by combining knowledge on the synthesis and catalytic 
activities of developing iridium species, with a series of theoretical (DFT) studies informing 
catalyst design and driving the establishment of even more active, selective, and widely 
applicable HIE catalysts.  This current review describes such recent advances in the 
development of iridium complexes as HIE catalysts and details the even wider array of organic 
substrates that can now undergo C-H activation and hydrogen isotope exchange in an 
effective and selective fashion. 
 
ENHANCED SUBSTRATE AND SOLVENT APPLICABILITY 
 
In all initial protocols utilising the catalysts from our laboratory, the solvent employed had been 
dichloromethane (DCM), which, despite the efficiency that is evidenced using catalysts 4, was 
deemed as a drawback to the established systems due to (i) the expected lack of applicability 
with all emerging drug-like substrates, and (ii) the associated hazards of chlorinated solvents, 
such as suspected carcinogenicity and high vaporisability.  In a drive to replace this less 
industrially-acceptable solvent, and to media that may well allow more effective substrate 
solubility, following a detailed screening study, t-BuOMe, Et2O, and 2-MeTHF all emerged as 
widely applicable labelling solvents for use with catalysts 4a-c.12  Importantly, work within our 
laboratory also expanded the research studies at this stage to include a theoretical approach, 
which provided further insight and understanding in relation to these solvent-based 
investigations. Computational methods have shown that, of the solvents discussed above, 
DCM binds least well to the activated iridium metal centre.  Furthermore, acetone, which was 
significantly less effective in labelling experiments of acetophenone, binds more strongly than 
the ethereal solvents.  Importantly, we also calculated the binding enthalpies associated with 
the exchange of a solvent molecule with the substrate to be labelled, namely acetophenone, 
which concluded that the balance between solvent and substrate binding enthalpies is crucial 
in determining the ability of the labelling reaction to occur.  More specifically, with DCM or the 
ethereal solvents listed above, the exchange of a solvent molecule by acetophenone is 
exothermic, whereas the same transformation with acetone occurs as part of a marginally 
endothermic process.12 
 
An effective practical example of such solvent effects was revealed in the isotopic labelling of 
Bayer’s anthelmintic, niclosamide 5 (Scheme 2).12 Employing catalyst 4a in DCM provided 
only moderate levels of labelling in each of the four positions at which exchange is expected, 
and with no significant site selectivity.  However, the deuteration of 5 within 2-MeTHF delivered 
appreciably improved overall levels of labelling at a reduced catalyst loading.  Such elevated 
labelling levels are proposed to be partially due to the higher solubility of niclosamide in the 2-
MeTHF solvent.  Additionally, a clear preference for H-D exchange through the more 
favourable 5-membered metallacyclic intermediate (5-mmi) versus a 6-mmi was noticeable in 
this ethereal medium.  Such an example illustrates the importance of expanding applicable 
HIE solvent systems beyond DCM, and to include media which are compatible with more polar 
drug molecules. 
 
 
 
Scheme 2: Solvent Effects in the Labelling of Niclosamide. 
 
In relation to substrate scope, further applicability of the catalysts emerging from our laboratory 
to a wider range of pharmaceutically-relevant heterocycles has been exemplified. Imidazole, 
oxazole, oxazoline, isoxazole, pyrimidine, and sulfur-containing thiazole substrates, as well as 
benzo-fused analogues, have been applied with very good levels of isotope incorporation 
under mild conditions and short reaction times.13  Illustrative examples are provided in 
Scheme 3.  It is also worth noting that in this same study, alternative solvents MeOH and THF 
were applied in the labelling of drug-like heterocycles with beneficial effect. 
 
  
 
Scheme 3: Labelling of Pharmaceutically-relevant Heterocycles. 
 
Further studies from our laboratory have gone on to establish the efficient, directed labelling 
of indole and pyrrole heterocycles, frameworks which, until recently, remained relatively 
underexplored classes of labelling substrates.14 Utilising common N-protecting groups to 
selectively direct C-H activation, high levels of deuterium incorporation have been achieved 
for a range of substrates, including the industrially-relevant sumatriptan 6, a 5-
hydroxytryptamine-receptor drug (Scheme 4). 
 
 
 
 
Scheme 4: Directed Labelling of Indole and Pyrrole Heterocycles and  
Synthesis of [D]Sumatriptan. 
 
A more focused study has also been reported using catalysts of type 4 with the ester 
functionality, a directing group that had presented a far less robust profile when applying the 
previously optimised reaction conditions.  Interestingly, it was found that performing reactions 
at a slightly elevated temperature of 40 °C significantly improved the levels of observed 
deuterium incorporation across a range of examples.15 
 
In addition to the installation of isotopic labels on aromatic positions, we have also investigated 
the use of these catalyst species to introduce deuterium at non-aromatic sp2 centres and, 
specifically, at the β-position of α,β-unsaturated systems (Scheme 5).16  Indeed, in order to 
label this class of substrates, careful consideration of the catalyst system was required in order 
to avoid competing alkene reduction.  Fortunately, it was found that, the triphenylphosphine-
containing complex 4b was able to deliver excellent levels of incorporation, with high levels of 
selectivity using only 0.1 mol% catalyst loading. 
 
 
 
Scheme 5: Labelling of Non-aromatic Unsaturated Functionality. 
 
FURTHER ACCESS TO LABELLED DRUGS AND DRUG-LIKE COMPOUNDS 
 
In addition to the optimisation and application of the iridium(I) species 4 within our own 
laboratory, there have been several reports of others employing such systems in order to gain 
access to labelled drugs and drug-like compounds.  One particularly notable example is the 
use of complex 4c by AstraZeneca isotope scientists in the synthesis of four tritiated drug 
molecules: [T]ethylmelagatran, [T]melagatran, [T]ximelagatran, and [T]hydroxymelagatran.17 
Carbamate-protected amidine 7 was selected as an intermediate which could be successfully 
labelled (Scheme 6) and subsequently transformed into the desired tritiated targets in a further 
one or two step procedure.  Whilst previous use of Crabtree’s catalyst (in stoichiometric 
quantities) had yielded less satisfactory levels of specific activity and radiochemical purity, the 
use of complex 4c, at only 10 mol% catalyst loading, furnished a sample of the labelled 
intermediate with appreciable levels of isotope incorporation and radiochemical purity, and 
beyond the minimal requirements of the study.  
 
 
 
Scheme 6: Tritiation of a Key AstraZeneca Drug Precursor. 
 
Another noteworthy example of the application of complex 4c is in the synthesis of tritiated 
AZD5248, a highly potent and selective cathepsin C inhibitor, which was required for 
preclinical metabolism studies.18  While direct labelling of AZD5248 proved challenging, due 
to the presence of the strongly coordinating nitrile groups within the final molecule, compound 
8 was selected as a suitable precursor.  Using the amide directing group, in conjunction with 
complex 4c, a sample of 9 was afforded with good levels of specific activity at 13.3 Ci/mmol 
(Scheme 7).  This compound was then dehydrated by reaction with the Burgess reagent, 
followed by Boc deprotection by stirring in formic acid.  This sequence successfully afforded 
the requisite radiolabelled sample of AZD5248.  In addition, AstraZeneca-based researchers 
have showcased further applications of catalysts 4 in the attempted production of labelled drug 
molecules.19 
 
 
 
Scheme 7: Preparation of Tritiated AZD5248. 
 
A further example of application of the catalyst system 4 comes from Skrydstrup and co-
workers.20  In this report, these researchers have disclosed a method for sp3-sp3 diboron 
compound reduction of H2O or D2O to produce hydrogen or deuterium gas, respectively, and 
for the resultant practically-convenient use of the in situ generated species within their two-
chamber reactor system.  While this report described a number of examples of this technique 
in hydrogenation (and associated reduction processes), notable examples of HIE using 
catalyst 4b were also showcased.  Using complex 4b at 5 mol% loading, a selectively 
deuterated sample of olaparib (an ovarian cancer drug) was accessed directly (Scheme 8).20  
In a similar and earlier approach with Zn/DCl/D2O in the Skrydstrup two chamber system to 
generate D2 gas (at 3 bar), labelled CX-546 (a schizophrenia treatment) was obtained with 
good levels of isotope incorporation (Scheme 8).21 
 
 
 
 
Scheme 8: HIE Using Skrydstrup’s Two-chamber Reactor System. 
 
COUNTERION EFFECTS 
 
A key breakthrough in this area of directed hydrogen isotope exchange was the preparation 
and application of further, novel, cationic iridium NHC/phosphine complexes bearing 
alternative counterions to the traditional hexafluorophosphate (PF6) ion present in our flagship 
catalysts 4.22  The assessment of a range of counterions, both larger and smaller than PF6, 
showed that the relative efficiency of each catalyst increases in order of increasing counterion 
volume.  Encouraged by research carried out by Pfaltz and others in iridium-based catalysis,23 
studies performed within our laboratory noted improved catalyst applicability and efficiency 
with Ir(I) NHC/phosphine complexes of type 10, containing the particularly diffuse BArF 
(tetrakis[3,5-bis(trifluoromethyl)phenyl]borate) counterion (Figure 2). 
 
 
 
Figure 2: BArF Complexes. 
 
Moving to this larger, more weakly coordinating, counterion facilitated the series to be operable 
in a more expansive array of solvent media beyond that which had already been reported.  A 
series of ethereal, alcoholic, ester, chlorinated, and aromatic solvents were shown to be 
applicable, with the more soluble BArF analogue outperforming the PF6 variant in all of the 
newly established media, as well as offering comparable levels of deuteration to already 
effective systems.  Whilst some variability was observed across a range of alcohol and ester 
solvents, more hindered such solvent species, such as t-AmOH and i-PrOAc, performed very 
well.  Additionally, a stark difference was observed in toluene, whereby BArF complex 10b 
proved almost twice as effective in the labelling of standard substrate acetophenone over 
parent complex 4b.  Notably, the utility of this improved solvent scope was demonstrated 
through widely enriched global deuterium labelling of the drug molecule niclosamide 5 in 2-
MeTHF (Scheme 9). 
 
 
 
Scheme 9: Deuteration of Niclosamide in 2-MeTHF. 
 
Our studies were extended to include a specific comparison of catalyst 4b, bearing the 
Ph3P/IMes and PF6 counterion combination, with the equivalent catalyst 10b, possessing the 
bulky, less coordinating BArF unit across a range of substrates.24  In DCM both catalysts 
performed equally well with substrates bearing ketone, ester, amide, and nitro directing groups 
(DGs) giving near quantitative incorporations at 5 mol% loading and under mild conditions. 
During these studies it was, however, observed that substrates containing two contending 
directing groups revealed solvent-dependent variations in the selectivity of labelling (Scheme 
10).  For example, for the labelling of 4-nitroacetophenone 11 in DCM both complexes 
exhibited similar selectivity and levels of labelling, with high deuterium incorporation observed 
adjacent to the ketone DG and, as anticipated, significantly reduced levels ortho to the nitro 
unit.  In THF, whilst a similar regioselectivity pattern was noted, the general level of deuterium 
incorporation was appreciably reduced, which perhaps indicates the requirement for a more 
hindered ethereal solvent, such as 2-MeTHF (vide supra).  Interestingly, whilst the ketone DG 
remained dominant in the HIE reaction in toluene, PF6 complex 4b displayed elevated levels 
of labelling ortho to the nitro DG, suggesting that the less electrophilic nature of 4b, combined 
with the weak coordination ability of toluene, allows for efficient binding of both DGs and, thus, 
for HIE to occur at both sites.  Indeed, the use of 10b re-established the selectivity of this 
process in line with this reasoning. 
 
As part of this same study the labelling of the antiandrogen drug, nilutamide 12, was assessed 
(Scheme 10).24  With complex 4b in DCM, almost quantitative levels of deuterium were 
incorporated ortho to the, normally weakly directing, nitro DG (via a 5-mmi), alongside a small 
amount of labelling being directed by the amide moiety through a 6-mmi. However, the use of 
complex 10b showed increased levels of selectivity, almost completely eliminating the 6-mmi 
labelling pathway. 
 
Overall, these comparison studies have shown that generally higher levels of labelling are 
achieved with catalyst 10b, possessing the less coordinating BArF counterion.  Additionally 
and importantly, these investigations also highlighted that a combination of catalyst 
counterion, substrate solubility, and associated solvent choice are key considerations in order 
to deliver requisite levels of site-selective isotope incorporation, and as will be more especially 
the case in more complex drug examples.  Complexes 10b and 10c, as readily handled and 
stored solids, are now commercially available from Strem Chemicals.  
 
 
 
Scheme 10: Comparison of PF6 vs BArF Catalysts. 
 
One particular class of pharmaceutically relevant heterocycles which did not prove amenable 
to the standard labelling conditions applied in previous examples was the tetrazole unit. 
Indeed, C-H functionalisations of aryl tetrazoles are rare, with the N-protected analogues often 
used as starting substrates.25-28  Despite this, studies within our laboratory aimed to exploit a 
different mode of reactivity, involving a concerted metalation-deprotonation (CMD) pathway, 
in order to utilise unprotected tetrazoles as directing groups for the installation of heavy 
isotopes of hydrogen.  In relation to this, a newly developed, base-assisted, protocol for the 
use of catalyst 10b in the labelling of aryl units possessing free aryl tetrazoles was disclosed 
in 2016.29  Through careful consideration of catalyst, base, temperature, and reaction time, 
optimised conditions delivering excellent levels of incorporation were achieved across a range 
of tetrazole-containing substrates (Scheme 11), and which also constituted the first examples 
of selective C-H activation and functionalisation of unprotected tetrazoles.  This system was 
also showcased in the tritium labelling of the antihypertensive drug, valsartan 13.  By running 
the reaction under 212-370 mbar of tritium gas, a sample of this angiotensin receptor blocker 
was afforded with 15 Ci/mmol and in excellent radiochemical purity. 
 
 
 
 
Scheme 11: Base-assisted Labelling of Unprotected Aryl Tetrazoles. 
 
NEUTRAL IRIDIUM SPECIES 
 
Whilst the established iridium(I) catalysts from our laboratory, bearing both phosphine and 
NHC ligands, had shown unprecedented scope in labelling reactions, more challenging motifs 
had been encountered, which were not accommodated with the required levels of 
effectiveness by this generation of catalysts.  For example, primary sulfonamides, which are 
prevalent in many drug-type molecules, showed only limited levels of incorporation when using 
the most active NHC/phosphine-type catalysts in our library.  Accordingly, it was proposed 
that a catalyst featuring a smaller ligand sphere, and a higher electron density, would favour 
the accommodation of sulfonamide-containing substrates leading to enhancement in the 
requisite C-H activation step and the subsequent ortho-labelling process.  Pleasingly, applying 
the chlorocarbene complex 14 (a synthetic precursor to the NHC-phosphine catalysts) to p-
toluenesulfonamide resulted in an impressive 90% deuterium incorporation, and which 
represented a substantial increase over the mere 12% achieved when employing catalyst 4b 
(Scheme 12).30  These results highlighted the dramatic change in activity which can be 
achieved by subtle changes in the catalyst parameters. 
 
 
 
Scheme 12: Labelling of p-Toluenesulfonamide. 
 
In order to optimise these parameters, studies within our laboratory utilised Nolan and 
Cavallo’s Percent Buried Volume (%Vbur)31 and modified Tolman Electronic Parameter 
(TEP)32,33 analyses to explore a number of analogues of catalyst 14.  Overall, complex 15, the 
most electron-rich of all complexes tested, was established as the optimal species for 
application with primary sulfonamides, facilitating the C-H activation and ortho-deuteration of 
a series of substrates, which required just 2 h reaction time under readily accessible conditions 
(Scheme 13).30a  Furthermore, we also established via competition studies the ability of 
complex 15 to selectively label p-toluenesulfonamide in the face of ketone, ester, nitro, and 
various amide directing groups within separate molecules.  Only the N-heterocycles, 1-
phenylpyrazole and 2-phenylpyridine, were able to compete with 15 to reverse the 
chemoselectivity of labelling.30a  Having stated this, based on contributing additional (steric 
and other) factors, it is important to note that this selectivity does not directly translate into 
multifunctional molecules, i.e. where the competing directing groups are present within the 
same molecule.  For example, when the more complex COX-2 inhibitor, celecoxib 16, 
possessing both a primary sulfonamide and a pyrazole unit, was applied under the previously 
optimised conditions with catalyst 15, the direction of labelling favoured deuterium insertion 
adjacent to the sulfonamide unit, which was in contrast to that recorded in the separate 
molecule competition and, indeed, reversed the direction of labelling obtained with catalyst 4b 
(Scheme 13).30a  Complex 15 is also now available commercially from Strem Chemicals. 
 
 
 
Scheme 13: Optimised Chloro-based Complex for HIE of Primary Sulfonamides. 
 
This methodology and the associated selectivity observations were underpinned by supporting 
theoretical studies, with the binding enthalpy (ΔHbind) and enthalpy of C—H insertion (ΔHins) 
calculated in order to support the experimental observations (Scheme 14).30a  Whilst it was 
found that the binding enthalpy of benzenesulfonamide was more exothermic for the activated 
form of the cationic, phosphine containing catalysts than the smaller, neutral chloride complex, 
in contrast to this, the C—H activation, predicted to be the rate determining step, was more 
endothermic for the cationic, phosphine-containing catalyst.  Such findings highlight the crucial 
nature of the catalyst ligand set; indeed, the reduced steric encumbrance of the chlorocarbene 
system in 15 relative to the standard phosphine analogue is vital for the successful HIE of 
primary sulfonamide substrates. 
 
 
 
Scheme 14: Calculations of Binding and C-H Insertion Energies. 
 
Shortly following the work just described, the emerging iridium chlorocarbene systems from 
our laboratory were more fully explored to further showcase their catalytic utility.  While many 
of the catalyst systems discussed thus far have targeted aryl-selective labelling through 
exploitation of a directing group, the application of the chlorocarbene type catalysts to aryl 
aldehydes opened a very different mode of reactivity.  When these neutral catalyst species 
are applied, instead of engagement of the aryl C-H bonds in close proximity to the aldehyde 
functionality, it is the formyl C-H unit which is preferentially activated and thus labelled.  The 
specific protocol was fully refined in order to tune the selectivity of the catalyst species and 
the associated process, resulting in complex 17 (Scheme 15).34  This novel technique exhibits 
noteworthy selectivity for the formyl position,35 with excellent levels of deuterium being 
incorporated into an array of aldehyde-containing substrates using only 1-2 mol% of the 
optimised catalyst 17.  Competing aryl labelling was only detected in a small number of 
substrates and at low levels in any given case.  In order to explain this change in reactivity, an 
alternate catalytic pathway involving a cis-arrangement of the catalyst ligands (as opposed to 
the trans-geometry present within mechanistic cycle established with the standard 
NHC/phosphine species11c) was proposed and supported by DFT calculations. 
 
 
 
Scheme 15: Labelling at the Formyl Position of Aldehydes. 
 
C(sp3) LABELLING 
 
With significant advancements in the area of HIE over the last decade having been mainly 
directed at aryl substrates, we and others have recently focused research towards the, rarer 
and more challenging, activation of C(sp3)-H bonds.  Indeed, the increasing demand for more 
structurally diverse, sp3-rich, 3D architectures as potential pharmaceuticals has resulted in 
endeavours to activate and functionalise such bonds gaining enhanced prominence.  In 
relation to HIE specifically, such methods would provide a complementary labelling pattern for 
existing substrates, whilst extending methodologies to non-aromatic molecules and those with 
aromatic portions that cannot currently be readily labelled.  Pleasingly, preliminary studies 
from our laboratory have shown that the highly active [Ir(COD)(PPh3)IMes]BArF complex 10b 
was effective in the sp3 labelling of a range of morpholines, piperidines, and piperazines at 
low catalyst loadings and under readily accessible conditions, with the label directed by an 
aza-heterocycle (Scheme 16).36  Some of the more challenging (acyclic) examples required 
a moderate increase in catalyst loading and reaction time, but were, nonetheless, successfully 
accommodated under comparatively mild conditions.  As well as a small number of open chain 
systems having been applied, the utility of the process was showcased by targeting active 
pharmaceuticals and other biological active species, including mirtazapine, azaperone, and 
caffeine, all of which were labelled to >90% incorporation at the sp3 site.  
 
 
 
Scheme 16: Csp3-labelling of Pharmaceutically-relevant Compounds. 
 
It has also recently been shown by Derdau and co-workers that the same catalyst (10b) is 
proficient in driving the HIE within aliphatic amide structures, to directly generate labelled 
amino acid and peptide products (Scheme 17).37  The challenging nature of these particular 
substrates required the more forcing conditions of iso-propyl acetate as the solvent at close to 
refluxing temperatures.  Nonetheless, this catalyst system allowed the efficient labelling of di-
, tri-, and even tetrapeptide structures.  Additionally, it is of note that disulfide structures were 
tolerated with up to 99% deuterium incorporation after just 3 h reaction time. 
 
 
 
Scheme 17: Labelling of Aliphatic Amide Structures. 
 
BIDENTATE CATALYST SYSTEMS 
 
Within this developing field of iridium-catalysed hydrogen isotope exchange, it has also 
emerged that the application of alternative P,N-ligated complexes can deliver notable levels 
of deuteration in a range of substrates.  Indeed, from research carried out within own 
laboratory in relation to the neutral chlorocarbene catalysts (e.g. 14, 15, and 17), it is expected 
that the cis arrangement of ligands within bidentate species results in electronically and 
sterically different complexes, which, indeed, could possibly lead to improved systems for 
HIE.30a,34 
 
The first example of the use of such bidendate species in HIE was in 2014 with Muri and co-
workers disclosing an effective protocol using Pfaltz’s PHOX-based ligands,38 species that 
were originally employed within asymmetric hydrogenation processes.  Despite the air- and 
moisture-sensitive nature of such complexes, a range of substrates with both strong directing 
groups such as pyridines, ketones, and amides, as well as weakly ligating units such as nitro 
and sulfonamides, were shown to incorporate deuterium at very good levels using only 5 mol% 
of a series of such catalyst species and, in particular, those possessing an electron-rich 
phosphorus unit, e.g. 18, at room temperature (Scheme 18).  Notably, Muri et al. were also 
able to introduce deuterium ortho to a secondary sulfonamide unit, albeit under more forcing 
conditions than their standard protocol.  Additionally, phenyl methyl sulfone was applied for 
the first time within such directed HIE procedures, and, with the addition of 
tris(pentafluorophenyl)borane to the reaction mixture, it was also shown that a normally highly 
deactivating nitrile substituent could be tolerated.  In the same publication, the authors 
disclosed a more accessible and achiral variant of Pfaltz’s original catalysts, again with a 
requirement for an electron-rich phosphorus moiety, which also proved to be a good catalyst 
for HIE, providing, generally, comparable results.  
 
 
 
 
Scheme 18: HIE Using Pfaltz’s Catalyst. 
 
Isotope chemists at Sanofi-Aventis in Frankfurt, Germany have identified that hydrogenation 
catalyst 19, developed by Burgess,39 can be applied in HIE with varying levels of efficiency.40  
It was illustrated that this commercial and air-stable catalyst facilitated the selective ortho-
deuteration of secondary and tertiary sulfonamides, and sulfonyl ureas, allowing, normally, 
less accessible deuterated products to be obtained at, up to, appreciable levels of 
incorporation, albeit at elevated temperatures in chlorobenzene.  The authors noted that a 
similar reactivity was observed when applying Kerr’s strategies with [(COD)Ir(IMes)Cl] 
complex 14 at 10 mol% under similarly forcing conditions, with this catalyst 14 typically proving 
most efficient in labelling secondary sulfonamides and sulfonyl ureas, and the Burgess catalyst 
19 delivering the highest levels of deuterium incorporation for tertiary sulfonamides (Scheme 
19).40  Interestingly, there was no deuterium delivered through a 6-mmi, for example in the N-
phenyl sulfonamide substrates, highlighting the challenge of accessing such an intermediate 
with these directing groups.  In this same publication, the authors also extended their scope 
to include the deuterium labelling of a series of sulfa drugs, as well as adapting the conditions 
to allow for selective tritium labelling.  
 
 
 
Scheme 19: Chloro-based Complex 14 vs Burgess’ Catalyst 19 for HIE of 2y and 3y 
Sulfonamides and Sulfonylureas. 
 
In a following publication the same year, the same researchers fully evaluated the use of the 
Burgess iridium(I)-catalyst 19, which proved competent in labelling a series of common 
functional groups, this time under ambient reaction conditions at 10 mol%.41  Ketones, 
aldehydes, amides (via both a 5- and 6-mmi), pyridines, and nitro directing groups were 
labelled at good to excellent levels.  Interestingly, sulfur-based directing groups were shown 
to label to moderate levels under these milder conditions. 
 
Inspired by the results from Muri et al., a collaborative study between the Sanofi laboratories 
and Tamm and co-workers recently evaluated the use of Tamm’s bidentate NHC-P complex 
20 in HIE reactions.42  This highly electron-rich ligand set facilitates the labelling of a wide 
range of directing groups to high levels (Scheme 20); while ketones, heterocycles, the nitro 
group, and esters were shown to be suitable, perhaps the most noteworthy results were those 
which employed a Boc unit to direct labelling into the aryl rings of anilines or heterocycles.42a  
The significant steric bulk of this Boc protecting group may usually render its use challenging; 
however, the chelated system present within Tamm’s catalyst allows for excellent levels of 
incorporation under mild conditions.  Furthermore, this system now also allows for 97% 
deuterium incorporation in phenyl methyl sulfone, and, at least as interestingly, in the absence 
of any competing directing groups, the benzylamine and methoxy motifs have shown directing 
group ability. 
 
 
 
Scheme 20: Evaluation of Tamm’s Bidentate Catalyst. 
 
Sanofi’s isotope chemists, alongside Tamm and co-workers, also established the ability of the 
same catalyst (20) to label highly hindered sulfonamides, N-oxides, and phosphonamides 
(Scheme 21).42b  Unlike previous attempts to label hindered sulfonamides with chlorocarbene 
catalyst 14, or, indeed, the Pfaltz and Burgess systems, the Tamm catalyst affords much 
higher levels of incorporation into N-substituted and N,N-disubstituted sulfonamides under 
appreciably more mild conditions. 
 
 
 
Scheme 21: Further Notable Examples Using Catalyst 20. 
 
Finally, and in a very recent addition to the use of bidentate iridium(I) complexes in HIE 
processes, Tamm and Derdau have established a catalytic protocol for the selective labelling 
of pharmacologically important phenylacetic acid esters and amides under mild reaction 
conditions.43  Employing Tamm’s P,N-ligated complex 20, >25 substrates have been labelled, 
via the more challenging 6-mmi, with deuterium incorporation up to 99%.  The authors have 
also adapted this method to the requirements of tritiation chemistry, and demonstrated the 
direct tritiation of the fungicide, benalaxyl, amongst other pharmaceutical compounds 
(Scheme 22). 
 
 
 
Scheme 22: HIE of Phenylacetic Acid Esters and Amides. 
 
CONCLUSIONS 
 
Isotopically labelled compounds form an essential part of drug discovery and development, 
particularly within the pharmaceutical industry, and direct methods such as ortho-directed C-
H activation and functionalisation using homogeneous catalysis has introduced a step-change 
in the ability to label pharmaceutical candidate molecules with radioactive (tritium) or non-
radioactive (deuterium) isotopes.  Following the emergence of iridium(I) NHC/phosphine-
based catalysts from our laboratory, species which are capable of incorporating high levels of 
deuterium (and tritium) to aromatic molecules under mild and efficient reaction manifolds, the 
field of iridium catalysis for HIE has been further and extensively diversified in terms of catalyst 
structure, key substrate scope, and mode of labelling.  The methods described in this review 
highlight the appreciable range of new and highly active iridium(I) catalysts that have been 
developed over the last decade for broadened application within novel C-H activation and 
hydrogen isotope exchange processes. 
 
Importantly, close collaborations between industry scientists and academic researchers have 
allowed strategic developments whereby substrate and synthetic target focus has guided and 
motivated catalyst design and application to very effectively create alignment with the 
requirements and goals of pharmaceutical partners and programmes.  It is clear that research 
to broaden the applicable directing groups and functionality amenable to selective labelling 
protocols remains highly pertinent and vibrant.  Specifically, a wider range of aromatic systems 
containing ketones, amides, esters, nitroarenes, an array of heterocycles, and various non-
aromatic unsaturated functionalities can be labelled under mild conditions, and, importantly, 
now in an array of solvents, in particular, using the BArF analogues of first generation catalysts.  
Furthermore, new catalyst systems, such as neutral chlorocarbene systems and P,N-ligated 
catalysts, have emerged as extremely effective species for installing key isotopes of hydrogen 
into new and previously inapplicable substrate classes, including sulfonamides, sulfones, and 
the formyl position of aryl aldehydes.  Additionally, labelling into rarer, and more challenging, 
C-sp3 hybridised centres has also started to emerge.   
 
The development of such systems, as described herein, have had direct impact within the 
laboratories of pharmaceutical partners, with the labelling of a range of drug molecules having 
been reported alongside catalyst and method development.  In many of these cases, only low 
(and generally less than 10 mol%) catalyst loadings are required, with ambient temperatures 
and gas pressures more than often sufficient to obtain the desired levels of labelling.   
 
From more recent studies, it has also become clear that the application of computational 
methods combined with experimental mechanistic investigations and kinetic studies are 
beginning to form a core component of this particular area of research.  In a number of recent 
examples, such approaches have led to a more comprehensive understanding of the 
emerging catalyst species and, in turn, have directly informed catalyst design.  As catalyst 
researchers and their pharmaceutical partners continue to strive to incorporate isotopic labels 
guided by an increasingly broadened array of functional units and within molecular frameworks 
of heightened complexity, and all with escalating levels of site selectivity, such blended 
theoretical, spectroscopic, and experimental strategies will become increasingly important in 
order to drive the design of catalysts for further enhanced, next generation HIE processes. 
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